May 2024 has been an exciting month for women’s health, with several significant advancements specifically in HPV testing and cervical cancer prevention. These innovations are are set to advance cervical health, as they help make screening more accessible, less invasive, and ultimately more effective in saving lives.
These developments align with the World Health Organization's (WHO) ambitious goal to eliminate cervical cancer as a public health issue by 2030. Achieving this goal involves widespread vaccination, regular screening, and timely treatment of precancerous conditions. Today our focus is on screening and more specifically screening for HPV.
HPV and Cervical Cancer: Understanding the Connection
Human Papillomavirus (HPV) is one of the most common sexually transmitted infections. Certain high-risk HPV types, such as HPV 16 and 18, are responsible for approximately 70% of cervical cancer cases. HPV can also cause throat and oral cancer, fertility problems, and other serious health issues. Early detection of HPV can lead to timely treatment and significantly reduce the risk of developing cervical cancer. Despite the availability of effective HPV vaccines, regular screening remains essential due to the vaccine's coverage limitations and the need to monitor existing infections.
The News in May and Why Self-Collection Matters
Self-collection solutions can be transformative for cervical cancer screening because they offer greater accessibility and convenience, both at home and in clinical settings. These solutions can help overcome barriers like geographic inaccessibility, financial constraints, and personal discomfort with traditional pelvic exams. By making it easier for women to participate in regular screenings, self-collection methods can significantly increase early detection rates and ultimately reduce cervical cancer incidence and mortality.
Having said that, let's now have a closer look at the solutions that have made headlines this month due to their advancements in self-collection.
BD’s Onclarity HPV Assay: BD has received FDA approval for a self-collection solution that allows women to collect vaginal specimens for HPV testing in various healthcare settings, including retail pharmacies and mobile clinics. This solution addresses barriers such as discomfort with pelvic exams, making it easier for more women to participate in regular screenings. More on this
Roche’s Cobas HPV Test: Roche’s recently FDA-approved self-collection solution enables individuals to privately collect their own samples, which are then analyzed in a laboratory. This method is part of Roche’s broader cervical cancer portfolio and aims to provide accurate and reliable results while reducing the need for clinician-collected procedures. More on this
Daye’s Diagnostic Tampon: Daye has expanded its at-home tampon-based screening kit to include HPV testing, leveraging PCR technology to allow women and AFAB (assigned female at birth) individuals to screen for 14 high-risk HPV infections. More on this
Teal Health’s Teal Wand: Teal Health has received FDA Breakthrough Device designation for its Teal Wand, an at-home self-collect cervical cancer screening device. Validated in a study with over 600 participants, the Teal Wand is designed for ease of use and accessibility, showing high user satisfaction and preference over traditional methods. More on this
Why It Matters: Addressing Screening Gaps
Cervical cancer is highly preventable with early detection. However, approximately 50% of cervical cancer cases occur in individuals who have never been screened, and 25% of women in the U.S. for example do not receive regular screenings.
Barriers such as geographic inaccessibility, financial insecurity, and personal discomfort with pelvic exams contribute to these gaps. Self-collection solutions could help bridge some of these these gaps by making screening more accessible and acceptable, particularly in underserved populations.
